Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 85

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 85
---
 and an immediate dilution in net tangible book value of $1.45 per share to investors purchasing from holders of the March 2024 Warrants and $1.31 per share to investors purchasing from holders of the August 2024 Warrants or October 2024 Warrants.

The following table illustrates the per share dilution to investors purchasing shares in an offering using this prospectus:

| Exercise price of March 2024 Warrants                                                             
 Exercise price of August 2024 Warrants and October 2024 Warrants                                  
 Net tangible book value per share as of March 31, 2025                                            |     |   | (0.04 | ) |     |   | 1.64 
 1.50 |
|:--------------------------------------------------------------------------------------------------|:----|:--|------:|:--|:----|:--|-----:|
| Pro forma net tangible book value per share                                                       |     | $ |  0.07 |   |     |   |      |
| Increase in pro forma net tangible book value per share attributable to this offering             |     | $ |  0.12 |   |     |   |      |
| Pro forma as adjusted net tangible book value per share after this offering                       |     |   |       |   |     | $ | 0.19 |
| Dilution in net tangible book value per share to investors purchasing from holders of March 2024  
 Warrants                                                                                          |     |   |       |   |     | $ | 1.45 |
| Dilution in net tangible book value per share to investors purchasing from holders of August 2024 
 Warrants or October 2024 Warrants                                                                 |     |   |       |   |     | $ | 1.31 |

The information above is based on 18,255,825 shares of Common Stock outstanding as of March 31, 2025, and excludes, as of that date:

| ● | 12,873,602                                                                                                         
 shares of Common Stock issuable upon the exercise                                                                  
 of outstanding warrants with a weighted average exercise price equal to $2.74 per share;                           |
| ● | 304,125                                                                                                            
 shares of Common Stock issuable upon the exercise                                                                  
 of stock options issued under our equity incentive plans with a weighted average exercise price equal to $6.95 per 
 share; and                                                                                                         |
| ● | 1,249,024                                                                                                          
 shares of our Common Stock that are